A blast from the past: To tame time with metformin

Mech Ageing Dev. 2022 Dec:208:111743. doi: 10.1016/j.mad.2022.111743. Epub 2022 Oct 22.

Abstract

The strong evidence of metformin use in subjects affected by type 2 diabetes (T2DM) on health outcomes, together with data from pre-clinical studies, has led the gerontological research to study the therapeutic potential of such a drug as a slow-aging strategy. However, despite clinical use for over fifty years as an anti-diabetic drug, the mechanisms of action beyond glycemic control remain unclear. In this review, we have deeply examined the literature, doing a narrative review from the metformin story, through mechanisms of action to slow down aging potential, from lower organisms to humans. Based on the available evidence, we conclude that metformin, as shown in lower organisms and mice, may be effective in humans' longevity. A complete analysis and follow-up of ongoing clinical trials may provide more definitive answers as to whether metformin should be promoted beyond its use to treat T2DM as a drug that enhances both healthspan and lifespan.

Keywords: Aging; Healthspan; Longevity; Mechanisms; Metabolism; Metformin.

Publication types

  • Review

MeSH terms

  • Aging
  • Animals
  • Diabetes Mellitus, Type 2* / drug therapy
  • Geriatrics*
  • Humans
  • Hypoglycemic Agents / pharmacology
  • Hypoglycemic Agents / therapeutic use
  • Longevity
  • Metformin* / pharmacology
  • Metformin* / therapeutic use
  • Mice

Substances

  • Metformin
  • Hypoglycemic Agents